The company’s Japan unit began rollouts for the Aurora EV-ICD MRI device and the Epsila EV MRI lead. They comprise the implantable cardioverter defibrillator (ICD) system that performs electrotherapy to restore a heart to a normal rhythm.
Aurora delivers defibrillation, anti-tachycardia pacing (ATP) and backup (pause-prevention) pacing therapies. It features a similar size, shape and longevity to traditional transvenous ICDs. However, the implant goes below the left armpit with the Epsila defibrillation lead placed under the breastbone. Medtronic says this helps avoid certain risks associated with transvenous ICDs that have leads placed inside the blood vessels.
[Get key insights on the surgical robotics market in our new Surgical Robotics Report]
The system also features anti-tachycardia pacing (ATP), a safe and effective feature for terminating ventricular tachycardia (VT). ATP restores the heart’s normal rhythm, briefly delivering pacing pulses to the heart at a faster rate than the tachycardia.
Medtronic received FDA approval for the Aurora EV-ICD MRI SureScan extravascular defibrillator in October 2023. The company reported positive long-term results for Aurora last fall as well.
“Medtronic has developed a wide range of innovative products to date, including leadless pacemakers. The compact Aurora EV-ICD system is one such product, and we are very pleased to be able to offer it to patients in Japan as a new option,” said Satoru Haga, VP of Cardiac Rhythm Management at Medtronic.
